Advances In the Development of New Quinazoline Based Anti-Cancer Agents

Authors

  • Jayanti S. Rajora   Department of Chemistry, Government Science College, Gandhinagar, Gujarat, India

Keywords:

Quinazolines, Anti-Cancer Activity.

Abstract

The growing knowledge of cancer-related pathways has recently resulted in the discovery of some novel potential targets for therapy, with quinazolines receiving increasing attention as small molecular inhibitors. The present paper covers a brief report of newer quinazoline based anti-cancer agents.

References

  1. Marzaro G, Guiotto A, Chilin A. Quinazoline derivatives as potential anticancer agents: a patent review (2007-2010). Expert Opin Ther Pat., 22, 223-252, 2012.
  2. V. Bavetsias et al. The Design and Synthesis of Water-Soluble Analogues of CB30865, a Quinazolin-4-one-Based Antitumor Agent. J. Med. Chem., 45, 3692-3702, 2002.
  3. Yang S. et al. Synthesis and bioactivity of 4-alkyl(aryl)thioquinazoline derivatives. Bioorg. Med. Chem. Lett., 17, 2193-2196, 2007.
  4. P. Mani Chandrika et al. Synthesis of novel 4,6-disubstituted quinazoline derivatives, their anti-inflammatory and anti-cancer activity (cytotoxic) against U937 leukemia cell lines. Eur. J. Med. Chem., 43, 846-852, 2008.
  5. R. Suthakaran et al. Inflammation: Synthesis and pharmacological  investigation of some new 4(3H)-Quinazolinone analogues as anti-oxidant, antihistaminic, anti-inflammatory and anti-tumor agents. Rasayan J. Chem., 1, 263-275, 2008. 9.    
  6. Saber El-Sayed Barakat et al. Novel Quinazolinone Derivatives as Possible Antitumor Agents. Phosphorus, Sulfur, and Silicon and the Related Elements, 182, 65-77, 2007.
  7. Alafeefy A. et al. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential anti-cancer agents. Journal of enzyme inhibition and medicinal chemistry, 27(4), 541-545, 2012.
  8. N. Mulakayala et al. InCl3-catalysed synthesis of 2-aryl quinazolin-4(3H)-ones and 5-aryl pyrazolo[4,3-d]pyrimidin-7(6H)-ones and their evaluation as potential anticancer agents. Bioorg. Med. Chem. Lett., 22, 5063-5066, 2012.
  9. Hurmath U. et al. Synthesis and in Vitro Anti Tumor Activity of Some Novel 2,3-Disubstituted Quinazolin 4(3H)-one Derivatives. Journal of Applied Pharmaceutical Science, 3 (10), 136-140, 2013.
  10. Smaill J. et al. Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenyl amino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions. J. Med. Chem., 43, 1380-1397, 2000.
  11. Wang Y. et al. Inhibitors of Src tyrosine kinase: the preparation and structure–activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines. Bioorg. Med. Chem. Lett., 10, 2477-2480, 2000.
  12. Barlaam B. et al. New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino) quinazolines as potent and selective c-Src kinase inhibitors. Bioorg. Med. Chem. Lett., 15, 5446-5449, 2005.
  13. Petrov K. et al. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series. Bioorg. Med. Chem. Lett., 16, 4686-4691, 2006.
  14. Lippa B. et al. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer. Bioorg. Med. Chem. Lett., 17, 3081-3087, 2007.
  15. Cha MY et al. Discovery of A Novel Her-1/Her-2 Dual Tyrosine Kinase Inhibitor for the Treatment of Her-1 Selective Inhibitor-Resistant Non-small Cell Lung Cancer. J. Med. Chem., 52, 6880-6888, 2009.
  16. Li Ri-Dong et al. Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines. Bioorg. Med. Chem. Lett., 21, 3637-3640, 2011.
  17. Li S. et al. Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-probe agents. Eur. J. Med. Chem., 65, 271-278, 2012.
  18. Zhang Y. et al. Synthesis and anticancer activities of 5,6,7-trimethoxy-N-phenyl(ethyl)-4-aminoquinazoline derivatives. Eur. J. Med. Chem., 66, 335-344, 2013.
  19. Garofalo A. et al. Impact of aryloxy-linked quinazolines: A novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett., 21, 2106-2112, 2011.
  20. Dohle W. et al. Quinazolinone-Based Anticancer Agents: Synthesis, Antiproliferative SAR, Antitubulin Activity, and Tubulin Co-crystal Structure. J Med Chem., 61(3):1031-1044, 2018.
  21. Govindraj Y. et al. Synthesis and In-vivo Anticancer Screening of 2-{[Bis-(2-Chloroethyl)Amino]Methyl}-6,8-Dinitro-1-(4-Substituted Ethyl)-1h-quinazolin-4-One Derivatives. Academic Journal of Cancer Research, 2(2), 73-77, 2009.
  22. Joseph A. et al. Synthesis and anticancer activity of some novel 3-(1,3,4-thiadiazol-2-yl)-quinazolin-4-(3H)-ones. Orbital-The Electronic Journal of Chemistry, 2(2), 158-167, 2010.
  23. Das S. et al. Anticancer Potential of 3-(Arylideneamino)-2- Phenylquinazoline-4(3H)-One Derivatives. Cell Physiol. Biochem., 29, 251-260, 2012.
  24. Ple P. et al. Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. Bioorg. Med. Chem. Lett., 22, 262-266, 2012.
  25. Noolvi M. et al. 2D QSAR Studies on a Series of Quinazoline Derivatives as Tyrosine Kinase (EGFR) Inhibitor: An Approach to Design Anticancer Agents. Letters in Drug Design & Discovery, 7, 56-586, 2010.
  26. Noolvi M. et al. 3D QSAR Studies on a Series of 4-Anilino Quinazoline Derivatives as Tyrosine Kinase (EGFR) Inhibitor: The k-Nearest Neighbor Molecular Field Analysis Approach. International Journal of Drug Design and Discovery, 1, 298-309, 2010.
  27. Noolvi M. et al. A Comparative QSAR Analysis of Quinazoline Analogues as Tyrosine Kinase (erbB-2) Inhibitors. Medicinal Chemistry, 7, 200-212, 2011.
  28. Mirzaie S. et al. Combined 3D-QSAR modeling and molecular docking study on multi-acting quinazoline derivatives as HER2 kinase inhibitors. EXCLI, 12, 130-142, 2013.

International Journal of Scientific Research in Science, Engineering and Technology

Downloads

Published

2017-08-30

Issue

Volume 3, Issue 5, July-August-2017

Section

Research Articles

License

Copyright (c) IJSRSET

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
Jayanti S. Rajora "Advances In the Development of New Quinazoline Based Anti-Cancer Agents" International Journal of Scientific Research in Science, Engineering and Technology (IJSRSET), Print ISSN : 2395-1990, Online ISSN : 2394-4099, Volume 3, Issue 5, pp.798-803, July-August-2017.